Publications by authors named "A Oriol"

Claim this Profile
T
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.
Ajai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, Katja Weisel, María-Victoria Mateos, Albert Oriol

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma.
Adela Cisneros, Mar Mallo, Aleix Méndez-López, Carmen Villena, Encarnación Santafé, Albert Oriol

Am J Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for the treatment of multiple myeloma.
Albert Oriol, Gladys Ibarra, Jordi Loscos, Laura Abril

Expert Opin Biol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, Jin Lu, Albert Oriol

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
María-Victoria Mateos, Bruno Paiva, M Teresa Cedena, Noemí Puig, Ana Maria Sureda-Balari, Albert Oriol

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis